Arvinas Doses First Patient in ARV-6723 Phase 1/2 Trial
NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...
Anti-PD-1
Advertisement
OSE to Present Phase 2 Tedopi Data in Metastatic NSCLC
NANTES, France — September 23, 2026 OSE Immunotherapeutics announced that topline results from the Combi-TED Phase 2 trial of...
GRAIL Advances Galleri FDA Review for Cancer Detection
Menlo Park, California, USA, August 8, 2026 GRAIL, Inc. has announced a major regulatory milestone as the U.S. Food...
Replimune Wins FDA Approval for TUDRIQEV in Melanoma
Woburn, Massachusetts, USA, August 8, 2026 Replimune Group, Inc. has achieved a significant regulatory milestone with the U.S. Food...
Henlius Wins CHMP Support for Serplulimab in Lung Cancer
Shanghai, China, May 23, 2026 Henlius Biotech has announced that the Committee for Medicinal Products for Human Use (CHMP)...
Advertisement
